This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomePrevnar 20®Prevnar 20®Serotypes matterAdministrationBurden of diseaseBurden
of diseasePneumococcal pneumoniaLinked Mega MenuBurden
of diseaseLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkIPDPatient profilesPatient
profilesAge 50+DiabetesAsthmaCOPDChronic heart diseaseRisk for all underlying medical conditionsClinical studiesClinical studiesBuilt on PCV13CAPiTAStudy 1 designStudy 1 resultsStudy 1 safetyStudy 6 designStudy 6 resultsStudy 6 safetyCDC recommendationsAccess & supportAccess & supportMedicareCommercial health plansMaterialsVideos
Prescribing InformationIndicationPatient SiteOrder Prevnar 20®
Invasive pneumococcal diseaseIPD is less common than pneumococcal pneumonia, but it can be severe1,2Certain underlying medical conditions can increase the risk of acquiring or dying from IPD1
Certain underlying medical conditions can increase the risk of acquiring or dying from IPD1

of pneumococcal disease cases in US adults over 50 were invasive in 2019.1

~3.6K
IPD deaths occurred in 2023 across all ages in the US3
~30%
of adult cases of IPD were in people aged 50 to 64 in 20233
IPD rates
peak at a younger age among Black adultscompared with non-Black adults,* making vaccination of adults in this population (aged 50-64) important4,5
of pneumococcal disease cases in US adults over 50 were invasive in 2019.1
~3.6K
IPD deaths occurred in 2023 across all ages in the US3
~30%
of adult cases of IPD were in people aged 50 to 64 in 20233
IPD rates
peak at a younger age among Black adults compared with non-Black adults,* making vaccination of adults in this population (aged 50-64) important4,5
Prevnar 20® helps protect against serotypes that can cause IPD5,6
View patient types eligible for Prevnar 20 Patient profiles LoadingReferencesIPD=invasive pneumococcal disease.
*CDC ABC Surveillance data 2018-2019 showed that IPD rates among Black adults peaked at a younger age (55-59 years) compared with rates among non-Black adults.4References:Thomas RE. Pneumococcal pneumonia and invasive pneumococcal disease in those 65 and older: rates of detection, risk factors, vaccine effectiveness, hospitalisation and mortality. Geriatrics (Basel). 2021;6(1):13. Kobayashi M. Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options. Presented at: Advisory Committee on Immunization Practices; October 20, 2021; Atlanta GA. Accessed May 19, 2025. https://stacks.cdc.gov/view/cdc/110908 Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report: Emerging Infections Program Network. Streptococcus pneumoniae, 2023. Updated March 20, 2025. Accessed May 20, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2023.pdf Kobayashi M. Summary of Work Group interpretation of EtR and policy options: PCV use in adults aged ≥50 years. Presented at: Advisory Committee on Immunization Practices; October 23, 2024; Atlanta, GA. Accessed October 23, 2024. https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/04-Kobayashi-Pneumococcal-508.pdf Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.Burden of disease Order Prevnar 20 for your office by registering for Prime Get started LoadingReferencesCAP=community-acquired pneumonia; CDC=Centers for Disease Control and Prevention; CSF=cerebrospinal fluid; ICU=intensive care unit; IPD=invasive pneumococcal disease.References:Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793-798.Garrouste-Orgeas M, Azoulay E, Ruckly S, et al. Diabetes was the only comorbid condition associated with mortality of invasive pneumococcal infection in ICU patients: a multicenter observational study from the Outcomerea Research Group. Infection. 2018;46:669-677.Data on file. Risk ratios. Pfizer Inc.Pelton SI, Bornheimer R, Doroff R, Shea KM, Sato R, Weycker D. Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization. Clin Infect Dis. 2019;68(11):1831-1838.Gierke R, Wodi AP, Kobayashi M. Pneumococcal disease. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. Centers for Disease Control and Prevention. 14th ed. Public Health Foundation; 2021;255-274.Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 21-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109-117.
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.Manufactured by Wyeth Pharmaceuticals LLC.
Marketed by Pfizer Inc.
PP-PNR-USA-3105 © 2025 Pfizer Inc.
All rights reserved. September 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-3105
You are now leaving PfizerPro You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.PP-MCL-USA-0367
INDICATION AND SELECT SAFETY INFORMATION
  • Prevnar 20® is a vaccine approved for:​​​​​
    • active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
    • active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
SELECT SAFETY INFORMATION
  • Do not administer Prevnar 20® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • In individuals 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in individuals 18 through 59 years of age
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.INDICATION
  • Prevnar 20® is a vaccine approved for:
    • active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
    • active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial